The present study describes the effect of kynurenic (KYNA) and 5,7-dichlorokynurenic (DCKA) acids, acting as selective antagonists at the glycine site on the NMDA receptor complex, upon short-term memory of male rats. Oxiracetam (OXIR) or pramiracetam (PRAM) were used as reference compounds. In the social recognition test, adult animals were injected SC with a drug or vehicle immediately after the first exposure to a juvenile male, 21-24 days old, and reexposed to the same or a novel juvenile 120 min later. Time spent by adults in social investigation of juveniles was measured. Animals treated with KYNA or DCKA (0.3, 3 and 30 mg/kg in both cases) and OXIR (30 and 60 mg/kg) had significantly reduced investigation time when reexposed to the same juvenile as compared to controls. No reduction of investigation time was found in those drugged animals reexposed to a novel juvenile. The findings suggest that KYNA and DCKA improved retention of memory for olfactory stimuli in adult male rats. In the object recognition test, the duration of exploration of two identical objects during the sample trial and the familiar and a new object during the choice trial, performed 60 min later, was evaluated. Drugs or vehicles were administered SC 30 min prior to the sample trial. On choice one, animals treated with KYNA or DCKA (0.6 and 30 mg/kg in both cases) and PRAM (30 mg/kg) spent more time in exploring a new object than the familiar one as compared to controls. This suggests that the drugged animals were able to remember the familiar object.(ABSTRACT TRUNCATED AT 250 WORDS)

Research Institute for Pharmacy and Biochemistry Prague 3 Czech Republic

Zobrazit více v PubMed

Brain Res. 1993 Feb 26;604(1-2):205-10 PubMed

Behav Brain Res. 1988 Nov 1;31(1):47-59 PubMed

Psychopharmacology (Berl). 1989;97(2):262-8 PubMed

Behav Neural Biol. 1993 Mar;59(2):150-7 PubMed

Psychopharmacology (Berl). 1994 May;114(4):644-50 PubMed

Neurochem Res. 1986 Mar;11(3):393-400 PubMed

Neurosci Lett. 1989 Jan 30;96(3):340-4 PubMed

Anal Biochem. 1988 Feb 15;169(1):89-94 PubMed

Neuropeptides. 1991 Jan;18(1):23-7 PubMed

Eur J Pharmacol. 1988 Sep 1;154(1):85-7 PubMed

Brain Res. 1982 Sep 9;247(1):184-7 PubMed

Nature. 1992 Oct 15;359(6396):638-41 PubMed

Ann Neurol. 1987 Dec;22(6):730-4 PubMed

Behav Pharmacol. 1992 Apr;3(2):129-131 PubMed

Ann N Y Acad Sci. 1992 May 11;648:140-53 PubMed

Behav Pharmacol. 1994 Jun;5(3):239-244 PubMed

Anal Biochem. 1990 Mar;185(2):363-76 PubMed

Eur J Pharmacol. 1988 Jul 7;151(2):313-5 PubMed

Neurosci Lett. 1988 Jul 19;90(1-2):208-12 PubMed

Psychopharmacology (Berl). 1990;102(4):551-2 PubMed

Neurosci Lett. 1990 Nov 27;120(1):31-3 PubMed

Mol Pharmacol. 1990 Oct;38(4):554-61 PubMed

Behav Brain Res. 1989 Jun 1;33(2):197-207 PubMed

Brain Res. 1988 Aug 2;457(1):143-7 PubMed

Psychopharmacology (Berl). 1991;104(4):505-9 PubMed

Neurology. 1991 Sep;41(9):1341-3 PubMed

Behav Neural Biol. 1993 Sep;60(2):89-92 PubMed

Behav Pharmacol. 1992 Aug;3(4):393-402 PubMed

Pharmacol Biochem Behav. 1989 Nov;34(3):649-53 PubMed

Physiol Res. 1991;40(1):59-67 PubMed

Pharmacol Biochem Behav. 1989 Dec;34(4):823-8 PubMed

Brain Res. 1988 Jun 28;454(1-2):164-9 PubMed

Neuropharmacology. 1993 May;32(5):461-6 PubMed

Physiol Behav. 1991 Dec;50(6):1253-6 PubMed

Brain Res. 1990 Feb 26;510(1):158-60 PubMed

J Neurosci. 1990 Sep;10(9):2965-73 PubMed

Neurosci Lett. 1989 Mar 13;98(1):91-5 PubMed

J Neurochem. 1988 Jul;51(1):177-80 PubMed

Brain Res. 1990 Apr 23;514(1):131-4 PubMed

Neurosci Lett. 1988 Nov 22;94(1-2):145-50 PubMed

Neurosci Lett. 1984 Aug 10;48(3):273-8 PubMed

Psychopharmacology (Berl). 1987;91(3):363-8 PubMed

Eur J Pharmacol. 1991 Feb 14;193(3):283-92 PubMed